JP2022525429A5 - - Google Patents
Info
- Publication number
- JP2022525429A5 JP2022525429A5 JP2021557650A JP2021557650A JP2022525429A5 JP 2022525429 A5 JP2022525429 A5 JP 2022525429A5 JP 2021557650 A JP2021557650 A JP 2021557650A JP 2021557650 A JP2021557650 A JP 2021557650A JP 2022525429 A5 JP2022525429 A5 JP 2022525429A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025021006A JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962825676P | 2019-03-28 | 2019-03-28 | |
| US201962825637P | 2019-03-28 | 2019-03-28 | |
| US62/825,676 | 2019-03-28 | ||
| US62/825,637 | 2019-03-28 | ||
| PCT/US2020/025533 WO2020198706A1 (en) | 2019-03-28 | 2020-03-27 | Compositions and methods for ttr gene editing and treating attr amyloidosis comprising a corticosteroid or use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021006A Division JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022525429A JP2022525429A (ja) | 2022-05-13 |
| JP2022525429A5 true JP2022525429A5 (https=) | 2023-12-15 |
| JPWO2020198706A5 JPWO2020198706A5 (https=) | 2023-12-15 |
| JP7636338B2 JP7636338B2 (ja) | 2025-02-26 |
Family
ID=70334147
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557650A Active JP7636338B2 (ja) | 2019-03-28 | 2020-03-27 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
| JP2025021006A Pending JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025021006A Pending JP2025081416A (ja) | 2019-03-28 | 2025-02-12 | コルチコステロイドを含む、ｔｔｒ遺伝子編集およびａｔｔｒアミロイドーシスを治療するための組成物および方法、またはその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230035659A1 (https=) |
| EP (1) | EP3946285A1 (https=) |
| JP (2) | JP7636338B2 (https=) |
| KR (1) | KR20220004984A (https=) |
| CN (1) | CN113874004A (https=) |
| AU (1) | AU2020248337A1 (https=) |
| CA (1) | CA3134544A1 (https=) |
| CO (1) | CO2021014562A2 (https=) |
| MX (1) | MX2021011690A (https=) |
| WO (1) | WO2020198706A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| CR20230305A (es) * | 2020-12-11 | 2023-11-10 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para la edición del genoma que implican desaminación |
| BR112023021477A2 (pt) * | 2021-04-17 | 2024-01-30 | Intellia Therapeutics Inc | Composições de nanopartículas lipídicas |
| WO2022246266A1 (en) * | 2021-05-21 | 2022-11-24 | Beam Therapeutics Inc. | Base editing of transthyretin gene |
| KR20240038705A (ko) * | 2021-06-22 | 2024-03-25 | 인텔리아 테라퓨틱스, 인크. | 간 유전자의 생체 내 편집 방법 |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| WO2024003805A1 (en) * | 2022-06-30 | 2024-01-04 | Geneditbio Limited | Methods and compositions for ttr gene editing and therapy using crispr system |
| CN120265763A (zh) * | 2023-10-25 | 2025-07-04 | 上海津曼特生物科技有限公司 | 靶向ttr的基因编辑组合物 |
| WO2025128871A2 (en) | 2023-12-13 | 2025-06-19 | Renagade Therapeutics Management Inc. | Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5378825A (en) | 1990-07-27 | 1995-01-03 | Isis Pharmaceuticals, Inc. | Backbone modified oligonucleotide analogs |
| KR940703846A (ko) | 1991-12-24 | 1994-12-12 | 비. 린네 파샬 | 갭(gap)이 형성된 2′ 변성된 올리고뉴클레오티드(gapped 2′ modifed oligonucleotides) |
| US6169169B1 (en) | 1994-05-19 | 2001-01-02 | Dako A/S | PNA probes for detection of Neisseria gonorrhoeae and Chlamydia trachomatis |
| WO2006007712A1 (en) | 2004-07-19 | 2006-01-26 | Protiva Biotherapeutics, Inc. | Methods comprising polyethylene glycol-lipid conjugates for delivery of therapeutic agents |
| AU2010223967B2 (en) * | 2009-03-12 | 2015-07-30 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes |
| DK2931898T3 (en) | 2012-12-12 | 2016-06-20 | Massachusetts Inst Technology | CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS |
| WO2014093694A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes |
| CA2895155C (en) | 2012-12-17 | 2021-07-06 | President And Fellows Of Harvard College | Rna-guided human genome engineering |
| EP3608308B1 (en) | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
| US20150165054A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting caspase-9 point mutations |
| MX2016007325A (es) * | 2013-12-12 | 2017-07-19 | Broad Inst Inc | Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos. |
| ES2895651T3 (es) | 2013-12-19 | 2022-02-22 | Novartis Ag | Lípidos y composiciones lipídicas para la administración de agentes activos |
| EP3169309B1 (en) | 2014-07-16 | 2023-05-10 | Novartis AG | Method of encapsulating a nucleic acid in a lipid nanoparticle host |
| EP3265559B1 (en) | 2015-03-03 | 2021-01-06 | The General Hospital Corporation | Engineered crispr-cas9 nucleases with altered pam specificity |
| ES2964690T3 (es) | 2015-09-21 | 2024-04-09 | Trilink Biotechnologies Llc | Método para sintetizar ARN con caperuza 5' |
| TWI773666B (zh) | 2016-03-30 | 2022-08-11 | 美商英特利亞醫療公司 | Crispr/cas 組分之脂質奈米粒子調配物 |
| WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
| WO2018067447A1 (en) | 2016-10-03 | 2018-04-12 | Itellia Therapeutics, Inc. | Improved methods for identifying double strand break sites |
| PT3688162T (pt) | 2017-09-29 | 2024-04-23 | Intellia Therapeutics Inc | Formulações |
| AR113154A1 (es) * | 2017-09-29 | 2020-01-29 | Intellia Therapeutics Inc | Polinucleótidos, composiciones y métodos para edición del genoma |
| EP3688161A1 (en) * | 2017-09-29 | 2020-08-05 | Intellia Therapeutics, Inc. | Compositions and methods for ttr gene editing and treating attr amyloidosis |
-
2020
- 2020-03-27 AU AU2020248337A patent/AU2020248337A1/en active Pending
- 2020-03-27 EP EP20720676.4A patent/EP3946285A1/en active Pending
- 2020-03-27 JP JP2021557650A patent/JP7636338B2/ja active Active
- 2020-03-27 KR KR1020217035012A patent/KR20220004984A/ko active Pending
- 2020-03-27 CA CA3134544A patent/CA3134544A1/en active Pending
- 2020-03-27 MX MX2021011690A patent/MX2021011690A/es unknown
- 2020-03-27 WO PCT/US2020/025533 patent/WO2020198706A1/en not_active Ceased
- 2020-03-27 CN CN202080039394.5A patent/CN113874004A/zh active Pending
-
2021
- 2021-09-27 US US17/486,758 patent/US20230035659A1/en not_active Abandoned
- 2021-10-28 CO CONC2021/0014562A patent/CO2021014562A2/es unknown
-
2025
- 2025-02-12 JP JP2025021006A patent/JP2025081416A/ja active Pending